US Map / North Dakota
State ND

Clinical Trials in North Dakota

North Dakota is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in North Dakota and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.

Right now ClinicalMetric tracks 27 actively recruiting studies with North Dakota sites out of 27 registered in total. The busiest research areas in North Dakota are Malignant Neoplasm, Solid Tumor, Untreated, Unresectable, or Metastatic Colorectal Cancer. Leading sponsors running trials in the state include National Cancer Institute (NCI), Merck Sharp & Dohme LLC, ECOG-ACRIN Cancer Research Group. By stage, North Dakota trials break down as Phase 1 (4), Phase 2 (10), Phase 3 (14).

All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.

Total Trials
27
Recruiting Now
27
← Back to US Map
Top Conditions in North Dakota
Malignant Neoplasm (2)Solid Tumor (2)Untreated, Unresectable, or Metastatic Colorectal Cancer (1)Advanced Malignant Solid Neoplasm (1)Anatomic Stage III Breast Cancer AJCC v8 (1)Anatomic Stage IV Breast Cancer AJCC v8 (1)Locally Advanced Malignant Solid Neoplasm (1)Malignant Female Reproductive System Neoplasm (1)Metastatic HER2-Negative Breast Carcinoma (1)Metastatic Malignant Solid Neoplasm (1)Recurrent Endometrial Carcinoma (1)Recurrent Fallopian Tube Carcinoma (1)

Frequently Asked Questions — Clinical Trials in North Dakota

How many clinical trials are currently recruiting in North Dakota?
ClinicalMetric currently tracks 27 actively recruiting clinical trials with at least one location in North Dakota. The total number of registered studies—including active but not currently enrolling trials—is 27. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in North Dakota?
North Dakota hosts clinical trials across a broad range of medical conditions, including Malignant Neoplasm, Solid Tumor, Untreated, Unresectable, or Metastatic Colorectal Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout North Dakota serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in North Dakota?
To join a clinical trial in North Dakota, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in North Dakota maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.

Recruiting Trials in North Dakota

NCT07221357 Phase 2, Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Che...
Condition
Untreated, Unresectable, or Metastatic Colorectal Cancer
Enrollment
990 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
View Trial →
NCT07252739 Phase 2
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants...
Condition
Malignant Neoplasm
Enrollment
140 pts
Location
United States, Chile, China
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT05564377 Phase 2
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally A...
Condition
Advanced Malignant Solid Neoplasm
Enrollment
2,900 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
View Trial →
NCT07571109 Phase 3
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps...
Condition
Obesity
Enrollment
300 pts
Location
United States, Australia, China
Sponsor
Novo Nordisk A/S
View Trial →
NCT04614103 Phase 2
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Condition
Metastatic Non Small Cell Lung Cancer
Enrollment
170 pts
Location
United States, Australia, Canada
Sponsor
Iovance Biotherapeutics, Inc.
View Trial →
NCT07630974 Phase 1, Phase 2
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refr...
Condition
Malignant Neoplasm
Enrollment
134 pts
Location
United States, Australia, Belgium
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06475989 Phase 3
Recruiting
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Condition
Refractory Differentiated Thyroid Gland Carcinoma
Enrollment
264 pts
Location
United States
Sponsor
ECOG-ACRIN Cancer Research Gro
View Trial →
NCT05486546 N/A
Recruiting
Contoura With Phorcides Compared to Wavefront Optimized LASIK
Condition
Myopia
Enrollment
120 pts
Location
United States
Sponsor
Daniel Terveen
View Trial →
NCT05642182 Phase 1
Recruiting
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
Condition
Psoriasis
Enrollment
90 pts
Location
United States
Sponsor
SFA Therapeutics
View Trial →
NCT03486873 Phase 3
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tum...
Condition
Solid Tumors
Enrollment
3,500 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06548360 Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa...
Condition
NonSegmental Vitiligo
Enrollment
180 pts
Location
United States, Canada
Sponsor
Incyte Corporation
View Trial →
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Tre...
Condition
Ganglioneuroblastoma, Nodular
Enrollment
478 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
View Trial →
NCT04165070 Phase 1, Phase 2
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) ...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
450 pts
Location
United States, Canada, Hungary
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06966700 Phase 3
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Br...
Condition
Breast Neoplasms
Enrollment
2,400 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT04181060 Phase 3
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With E...
Condition
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Enrollment
300 pts
Location
United States
Sponsor
National Cancer Institute (NCI
View Trial →
NCT03866382 Phase 2
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) ...
Condition
Bladder Adenocarcinoma
Enrollment
314 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
View Trial →
NCT07357727 Phase 3
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Condition
Primary Myelofibrosis (PMF)
Enrollment
460 pts
Location
United States, Argentina, Australia
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT04566328 Phase 3
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Mu...
Condition
Plasma Cell Myeloma
Enrollment
1,450 pts
Location
United States, Puerto Rico
Sponsor
ECOG-ACRIN Cancer Research Gro
View Trial →
NCT02332668 Phase 1, Phase 2
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced So...
Condition
Melanoma
Enrollment
370 pts
Location
United States, Brazil, France
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07437950 Phase 2
Recruiting
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly ...
Condition
Acute Myeloid Leukemia
Enrollment
126 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
View Trial →
NCT06422806 Phase 3
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone f...
Condition
Metastatic Dedifferentiated Liposarcoma
Enrollment
365 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
View Trial →
NCT06207032 N/A
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Condition
Cancer
Enrollment
500 pts
Location
United States, Puerto Rico
Sponsor
Tempus AI
View Trial →
NCT00736749 N/A
Recruiting
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Gro...
Condition
Hematopoietic Cell Transplantation Recipient
Enrollment
25,000 pts
Location
United States, Puerto Rico
Sponsor
Children's Oncology Group
View Trial →
NCT03072927 N/A
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Condition
Lumbar Spinal Stenosis
Enrollment
8,000 pts
Location
United States
Sponsor
Stryker Instruments
View Trial →
NCT06524544 Phase 3
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hzi...
Condition
Locally Advanced Urothelial Carcinoma
Enrollment
320 pts
Location
United States
Sponsor
National Cancer Institute (NCI
View Trial →
Page 1 of 2 — 27 trials total
Next →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology